Pemetrexed disodium heptahydrate is chemotherapeutic agent and it falls in the class of anti-metabolites. It is supplied as a sterile lyophilized powder for intravenous infusion available in single-dose vials. Each 100-mg or 500-mg vial of ReliTrexed® contains pemetrexed disodium equivalent to 100 mg pemetrexed or 500 mg.

Pemetrexed is indicated in combination with cisplatin therapy, for the initial treatment of patients, with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). It is also indicated in combination with pembrolizumab and platinum chemotherapy, for metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. It is used as a single agent for the treatment of patients, with locally advanced or metastatic nonsquamous NSCLC, after prior chemotherapy and in combination with cisplatin. It is indicated for patients with malignant mesothelioma, when the disease is unresectable, or, for those, who are otherwise not candidates for curative surgery.

ReliTrexed® is available in 100 and 500 mg vials.